Quantitative assessment of interstitial lung disease in Sjögren’s syndrome

Autoři: Pablo Guisado-Vasco aff001;  Mario Silva aff002;  Miguel Angel Duarte-Millán aff003;  Gianluca Sambataro aff004;  Chiara Bertolazzi aff005;  Mauro Pavone aff004;  Isabel Martín-Garrido aff001;  Oriol Martín-Segarra aff001;  José Manuel Luque-Pinilla aff001;  Daniele Santilli aff006;  Domenico Sambataro aff007;  Sebastiano E. Torrisi aff004;  Ada Vancheri aff004;  Marwin Gutiérrez aff005;  Mayra Mejia aff008;  Stefano Palmucci aff009;  Flavio Mozzani aff006;  Jorge Rojas-Serrano aff008;  Carlo Vanchieri aff004;  Nicola Sverzellati aff002;  Alarico Ariani aff006
Působiště autorů: Internal Medicine, Complejo hospitalario Ruber Juan Bravo, Universidad Europea (Madrid), Madrid, Spain aff001;  Scienze Radiologiche, Dipartimento di Medicina e Chirurgia (DiMeC), University of Parma, Parma, Italy aff002;  Internal Medicine, Hospital universitario Fuenlabrada, Fuenlabrada, Spain aff003;  Regional Referral Center for Rare Lung Diseases, A. O. U. "Policlinico-Vittorio Emanuele" Dpt. of Clinical and Experimental Medicine, University of Catania, Catania, Italy aff004;  Division of Musculoskeletal and Rheumatic Disorders, Instituto Nacional de Rehabilitación—“Luis Guillermo Ibarra Ibarra”, Mexico City, Mexico aff005;  Internal Medicine and Rheumatoloy Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy aff006;  Department of Clinical and Experimental Medicine, Internal Medicine Unit, Cannizaro Hospital, University of Catania, Catania, Italy aff007;  Interstitial Lung Disease and Rheumatology Unit, Instituto Nacional de Enfermedades Respiratorias, Ismael Cosio Villegas, Mexico City, Mexico aff008;  Department of Medica Surgical Sciences and Advanced Technologies "GR Ingrassia", Radiology I unit, University of Catania, Catania, Italy aff009
Vyšlo v časopise: PLoS ONE 14(11)
Kategorie: Research Article
doi: 10.1371/journal.pone.0224772



Interstitial lung disease (ILD) is a frequent manifestation of Sjögren’s syndrome (SS), an autoimmune disease of salivary and lacrimal glands, and affects approximately 20% of patients. No clinical or serological features appear to be useful to predict its presence, severity or progression, and chest high-resolution computed tomography (CT) remains the gold standard for diagnosis. Semiquantitative CT (SQCT) based on visual assessment (Goh and Taouli scoring) can estimate ILD extent, although it is burdened by relevant intra- and interobserver variability. Quantitative chest CT (QCT) is a promising alternative modality to assess ILD severity.


To determine whether QCT assessment can identify extensive or limited lung disease in patients with SS and ILD.


This multi-center, cross-sectional and retrospective study enrolled patients with SS and a chest CT scan. SQCT assessment was carried out in a blinded and centralized manner to calculate both Goh and Taouli scores. An operator-independent analysis of all CT scans with the open-source software platform Horos was used to evaluate the QCT indices. Patients were classified according to the extent of ILD and differences in QCT index distribution were investigated with non-parametric tests.


From a total of 102 consecutive patients with SS, the prevalence of ILD was 35.3% (36/102). There was a statistically significant difference in QCT index distribution between the SS with ILD and SS without ILD groups (p<0.001). Moreover, SS-ILD patients with ILD >20% (by Goh score) had a QCT index statistically different from those with limited ILD extent (p<0.001). Finally, QCT indices showed a moderate-to-good correlation with the Goh and Taouli scores (from 0.44 to 0.65; p<0.001).


QCT indices can identify patients with SS and ILD and discriminate those with lesser or greater lung disease.

Klíčová slova:

Autoimmune diseases – Computed axial tomography – Pneumonia – Pulmonary function – Salivary glands – Statistical data – Statistical distributions – Interstitial lung diseases


1. Gao H, Zou YD, Zhang XW, He J, Zhang J, Sun Y et al. Interstitial lung disease in non-sicca onset primary Sjögren’s syndrome: a large-scale case-control study. Int J Rheumatol Dis 2018; 21(7):1423–1429.

2. Ramos-Casals M, Brito-Zerón P, Seror R, Bootsma H, Bowman SJ, Dörner T et al on behalf of, EULAR Sjögren Syndrome Task Force. Characterization of systemic disease in primary Sjögren’s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology (Oxford) 2017; 54(12):2230–2238.

3. Delaleu N, Mydel P, Kwee I, Brun JG, Jonsson MV, Jonsson R. High fidelity between saliva proteomics and the biologic state of salivary glands defines biomarker signatures for primary Sjögren’s syndrome. Arthritis Rheumatol 2015; 67:1084–1095. doi: 10.1002/art.39015 25545990

4. Fischer A, Swigris JJ, du Rois RM, Groshong SD, Cool CD, Sahin H et al. Minor salivary gland biopsy to detect primary Sjögren’s syndrome in patients with interstitial lung disease. Chest 2009; 136(49): 1072–1078.

5. Ciancio N, Pavone M, Torrisi SE, Vancheri A, Sambataro D, Palmucci S, et al. Contribution of pulmonary function tests (PFTs) to the diagnosis and follow up of connective tissue diseases. Multidisclip Respir Med 2019;14:17 doi: 10-1186/s40248-019-01792 eCollection 2019.

6. Dong X, Zhou J, Gou X, Li Y, Xu Y, Fu Q et al. A retrospective analysis of distinguishing features of chest HRCT and clinical manifestation in primary Sjögren’s syndrome-related interstitial lung disease in a Chinese population. Clin Rheumatol 2018;37(11): 2981–2988. doi: 10.1007/s10067-018-4289-6 30242640

7. Wang Y, Hou Z, Qiu M, Ye Q. Risk factors for primary Sjögren’s syndrome-associated lung disease. J Thorac Dis 2018; 10(4): 2108–2117. doi: 10.21037/jtd.2018.03.120 29850114

8. Flores-Chavez A, Kostov B, Solans R, Fraile G, Maure B, Feijoó-Massó C et al. Severe life-threating phenotype of primary Sjögren’s syndrome: clinical characterization and outcomes of 1580 patients (GEAS-SS Registry). Clin Exp Rheumatol. 2018;36 Suppl 112(3):121–129.

9. Flament T, Bigot A, Chaigne B, Henique H, Diot E, Marchand-Adam S. Pulmonary manifestations of Sjögren’s disease. Eur Resp Rev 2016;25 (140):110–123.

10. Kampolis CF, Fragkioudaki S, Mavragani CP, Zormpala A, Samakovli A, Moutsopoulos HM. Prevalence and spectrum of symptomatic pulmonary involvement in primary Sjögren’s syndrome. Clin Exp Rheumatol 2018; 36 (Suppl 112) S91–101.

11. Gao H, Zhang ZW, He J, Zhang J, An Y, Sun Y et al. Prevalence, risk factors, and prognosis of interstitial lung disease in a large cohort of Chinese primary Sjögren’s syndrome patients: A case-control study. Medicine (Baltimore) 2018; 97(24):e11003.

12. Sebastian A, Misterska-Skóra M, Silicki J, Sebastian M, Wiland P. Chest HRCT findings in patients with primary Sjögren’s syndrome. Adv Clin Exp Med 2017; 26(7):1101–1106. doi: 10.17219/acem/68978 29211358

13. Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177(11):1248–54. doi: 10.1164/rccm.200706-877OC 18369202

14. Tauli B, Brauner MW, Mourey I, Lemouchi D, Grenier PA. Thin-section chest CT findings of primary Sjögren’s syndrome: correlation of pulmonary function. Eur Radiol 2002; 12:1504–1511. doi: 10.1007/s00330-001-1236-7 12042961

15. Herth FJF, Kirby M, Sieren J, Herth J, Schrim J, Wood S et al. The modern art of reading computer tomography images of the lungs: quantitative CT. Respiration 2018; 95(1):8–17. doi: 10.1159/000480435 28918422

16. Ariani A, Silva M, Bravi E, Saracco M, Parisi S, de Gennaro F, et al. Operator-independent quantitative chest computed tomography versus standard assessment of interstitial lung disease related to systemic sclerosis: a multi-center study. Mod Rheumatol 2015; 25(5):724–30. doi: 10.3109/14397595.2015.1016200 25736361

17. Sumikawa H, Jontok T, Yamamoto S, Yanagawa M, Inoue A, Honda O et al. Computed tomography values calculation and volumen histogram analysis for various compute tomographic patterns of diffuse lung diseases. J Comput Assist Tomogr 2009; 33(5):731–738. doi: 10.1097/RCT.0b013e31818da65c 19820502

18. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman LM et al. International Sjögren’s Syndrome criteria working group. 2016 American College of Rheumatology/ European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis 2017; 76(1):9–16. doi: 10.1136/annrheumdis-2016-210571 27789466

19. Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP et al. The strengthening the Reporting of Observational Studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLos Med 2007; 4(10): e296. doi: 10.1371/journal.pmed.0040296 17941714

20. Ash SY, Harmouche R, Vallejo DL, Villalba JA, Ostridge K, Gunville R et al. Densitometric and local histogram-based analysis of computed tomography images of patients with idiopathic pulmonary fibrosis. Respir Res 2017; 18(1):45. doi: 10.1186/s12931-017-0527-8 28264721

21. Sambataro G, Ferro F, Orlandi M, Sambataro D, Torrisi SE, Quartuccio L, et al. Clinical, morphological features and prognostic factors associated with Interstitial Lung Disease in primary Sjögren’s Syndrome: a systematic review from the Italian Society of Rheumatology. Autoimmun Rev, forthcoming

22. Ariani A, Silva M, Bravi E, Saracco M, Parisi S, de Gennaro F, et al. Quantitative chest computed tomography is associate with two prediction models in interstitial lung disease related to systemic sclerosis. Rheumatology (Oxford) 2017; 56(6):922–927.

23. Moore OA, Goh NS, Corte T, Rouse H, Hennessy O, Thakkar V et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology 2013; 52(1):155–160. doi: 10.1093/rheumatology/kes289 23065360

24. Jacob J, Bartholmai BJ, Rajagopalan S, Brun AL, Egashira R, Karwoski R. Evaluation of computer-based computer tomography stratification against outcome models in connective tissue disease-related interstitial lung disease: a patient outcome study. BMC Med 2016; 14(1):190. doi: 10.1186/s12916-016-0739-7 27876024

25. Gao H, Zou YD, Zhang XW, He J, Zhang J, Sun Y et al. Interstitial lung disease in non-sicca onset primary Sjögren’s syndrome a large-scale case-control study. Int J Rheum Dis 2018; 21(7):1423–1429. doi: 10.1111/1756-185X.13334 29968329

26. Chen MH, Chou HP, Lai CC, Chen YD, Chen MH, Lin HY et al. Lung involvement in primary Sjögren’s syndrome: correlation between high-resolution computed tomography score and mortality. J Chin Med Asocc 2014; 77(2):75–82.

27. Brito-Zerón P, Acar-Denizili N, Ng WF, Zeher M, Rasmussen A, Mandl T et al. How immunological profile drives clinical phenotype of primary Sjögren’s syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project). Clin Exp Rheumatol 2018; 36 (Suppl. 112): S102–S112.

28. Fonseca VR, Romão VC, Agua-Doce A, Santos M, López-Presa D, Ferreira AC. The ratio of blood T follicular regulatory cells to follicular helper cells marks ectopic lymphoid structure formation while activated follicular helper T cells indicates disease activity in primary Sjögren’s syndrome. Arthritis Rheumatol 2018; 70(5):774–784. doi: 10.1002/art.40424 29361207

29. Reale M, D’Angelo C, Costantini E, Laus M, Moretti A, Croce A. MicroRNA in Sjögren’s syndrome: their potential role in pathogenesis and diagnosis. J Immunol Res 2018 Jun 7; 2018:7510174. doi: 10.1155/2018/7510174 eCollection 2018. 29977932

30. Guisado-Vasco P, de Luna Cardenal G, Martin-Garrido I, Luque-Pinilla JM, Fraile-Rodriguez G, Mateo JJ et al. Assessment of interstitial lung disease in Sjögren’s syndrome by lung ultrasound: a pilot study of correlation with high-resolution chest tomography. Intern Emerg Med 2017; 12(3):327–331. doi: 10.1007/s11739-016-1582-8 27900604

31. Brito-Zerón P, Acar-Denzili N, Zeher M, Rasmussen A, Seror R, Theander E etl al. Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren’s syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium. Ann Rheum Dis 2017; 76(6): 1042–1050. doi: 10.1136/annrheumdis-2016-209952 27899373

32. Silva M, Milanese G, Seletti V, Ariani A, Sverzellati N. Pulmonary quantitative CT imaging in focal and diffuse disease: current research and clinical applications. Br J Radiol 2018; 91(1083):2017064. doi: 10.1259/brj.20170644

33. Judge PA, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S et al. MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N Engl J Med 2018; 379(23):2209–2219. doi: 10.1056/NEJMoa1801562 30345907

34. Chong DY, Kim HJ, Lo P, Young S, McNitt-Gray MF, Abtin F, et al. Robustness driven feature selection in classification of fibrotic interstitial lung disease patterns in computed tomography using 3D texture feature. IEEE Trans Med Imaging 2016; 35:144–57. doi: 10.1109/TMI.2015.2459064 26208309

35. Thompson G, Mclean-Tooke A, Wrobel J, Lavender M, Lucas M. Sjögren’s syndrome with associated with lymphocytic interstitial pneumonia successfully treated with tacrolimus and abatacept as an alternative to rituximab. Chest 2018; Mar; 153(3):e41–e43. doi: 10.1016/j.chest.2017.12.010 29519308

36. Yamano Y, Taniguchi H, Kondoh Y, Ando M, Kataoka K, Furukawa T et al. Multidimensional improvement in connective tissue disease-associated interstitial lung disease: two courses of pulse dose methylprednisolone followed by low-dose prednisone and tacrolimus. Respiratology 2018; 23(11):1041–1048.

Článek vyšel v časopise


2019 Číslo 11